Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 0 86 SODIUM CHLORIDE IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 0 86 SODIUM CHLORIDE IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced afterload.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion: Initial dose 5 mg/hour, titrate by 2.5 mg/hour every 5 minutes as needed to maximum 15 mg/hour. For maintenance, reduce to 3 mg/hour after blood pressure controlled. Label strength: 0.1 mg/mL in 0.86% NaCl.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal half-life 8.6 hours; in hepatic impairment, half-life may be prolonged up to 2-fold
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal (70-80% as metabolites, <1% unchanged), fecal (20-30%)
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."